Therapeutic effects of reslizumab in patients with severe eosinophilic asthma
Respiratio · 2026 · 16 (1-2) · 9-14
DOI: 10.5937/respira2602009b ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiratio, 2026. Verfasst von Borislav Božanić und 12 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Introduction
The beneficial therapeutic effects of anti-IL-5 biological therapy in severe asthma have been confirmed in randomized controlled trials. The aim of this study was to evaluate the effects of reslizumab therapy in patients with severe eosinophilic asthma.
Methods
This retrospective-prospective study included 18 patients. The following parameters were analyzed: age, body mass index (BMI), and the number of administered doses of biological therapy; absolute peripheral blood eosinophil count - BEC (cells/μL), at baseline and after three months of therapy; baseline fractional exhaled nitric oxide (FeNO) levels and total IgE levels; as well as prebronchodilator FEV₁ and Asthma Control Test (ACT) scores, at baseline and during twelve months of therapy.
Results
All patients in the study group were female, with a mean age of 53.9 years and a mean BMI of 29.1 kg/m². An average of 12.25 doses of the drug was administered. The baseline BEC was 402.3 cells/ μL; administration of the first dose resulted in a statistically significant reduction after 24 hours, which was maintained after three months of follow-up. The mean FeNO value was 30.1 ppb, and the mean total IgE level was 160.9 IU/mL. The mean baseline FEV₁ was 57.7% of predicted, with higher values maintained throughout the follow-up period. The mean ACT score before initiation of therapy was 10.8 and was significantly higher during further follow-up.
Conclusion
Biological therapy with reslizumab in overweight and obese female patients with a confirmed diagnosis of severe asthma and elevated biomarkers of the Th2 immune response results in a significant reduction in symptoms and stabilization of lung function, achieving adequate disease control in more than three-quarters of patients. The therapeutic effects are maintained over a one-year follow-up period.
Zitieren
APA
Božanić, B., Stanković, I., Šajnović, S., Rančev, N., Srbulović-Božanić, A., Aleksić, J., Stojiljković, D., Jović, K., Marinković, M., Stamenković, Z., Radović, M., Pejčić, T., & Nastasijević-Borovac, D. (2026). Therapeutic effects of reslizumab in patients with severe eosinophilic asthma. Respiratio, 16(1-2), 9-14. https://doi.org/10.5937/respira2602009b
Vancouver
Božanić B, Stanković I, Šajnović S, Rančev N, Srbulović-Božanić A, Aleksić J, et al. Therapeutic effects of reslizumab in patients with severe eosinophilic asthma. Respiratio. 2026;16(1-2):9-14. doi:10.5937/respira2602009b
BibTeX
@article{Boani2026,
author = {Božanić, Borislav and Stanković, Ivana and Šajnović, Stefan and Rančev, Nikola and Srbulović-Božanić, Ana and Aleksić, Jelena and Stojiljković, Dragana and Jović, Kristina and Marinković, Marija and Stamenković, Zoran and Radović, Milan and Pejčić, Tatjana and Nastasijević-Borovac, Desa},
title = {Therapeutic effects of reslizumab in patients with severe eosinophilic asthma},
journal = {Respiratio},
year = {2026},
volume = {16},
number = {1-2},
pages = {9--14},
doi = {10.5937/respira2602009b}
}
EUVIMED